
Pharma Hemp®
LABORATORIES

CERTIFICATE OF ANALYSIS No.: 2026-19044

CLIENT
USA MEDICAL KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG, Alkotás u. 53/A
1123 Budapest, Hungary

SAMPLE *
USA medical 500 mg CBD oil





Sample condition:	SUITABLE	Work order:	2026-113542	Sample received:	11/09/2026
Sample ID:	2637039	Analysis ID:	2026_277	Start of analysis:	15/09/2026
Sample type:	Viscous liquid	Method ID:	PHL_RPC_16C	End of analysis:	23/09/2026
Batch No.: *	NKS502606-01	Method SOP:	MET-LAB-001-08	Analyst:	Jhansi L.K. Mamilla

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	< LOQ	n/a	
CBD	- Cannabidiol	1.931	0.097	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	< LOQ	n/a	
Δ^9-THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
Δ^8-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ^9-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	< LOQ	n/a	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
CBT	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ	n/a	

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

23/09/2026

Approved by:

mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate